Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | ALPL | P05186 | 8/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23847019 | 0.86 | MEN1 (0.61) | RECQLALDH1A1SMN1; SMN2ALPLGAA | |
| SCHEMBL23846503 | 0.84 | SMN1; SMN2 (0.71) | RECQLALDH1A1SMN1; SMN2ALPLGAA | |
| SCHEMBL17980891 | 0.83 | MAPT (0.60) | ALDH1A1SMN1; SMN2ALPLGAALMNA | |
| SCHEMBL25754817 | 0.83 | NPSR1 (0.62) | POLBSMN1; SMN2ALPLLMNA | |
| SCHEMBL23846500 | 0.83 | LMNA (0.73) | RECQLALDH1A1SMN1; SMN2ALPLGAA | |
| SCHEMBL23833737 | 0.83 | MEN1 (0.63) | RECQLSMN1; SMN2ALPLLMNA | |
| SCHEMBL23847027 | 0.82 | MEN1 (0.59) | RECQLALDH1A1SMN1; SMN2ALPLGAA | |
| SCHEMBL23846527 | 0.82 | ALPL (0.51) | RECQLALDH1A1POLBSMN1; SMN2ALPL | |
| SCHEMBL23846529 | 0.81 | ALPL (0.60) | SMN1; SMN2ALPLGAALMNA | |
| SCHEMBL23833741 | 0.79 | RECQL (0.67) | RECQLALDH1A1POLBSMN1; SMN2ALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| EP-4121029-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | Amathus Therapeutics, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| WO-2021188880-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | TRAP1, PINK1, TP53BP1 | RECQL 948/4885ALDH1A1 2569/4885POLB 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.